Parkinson’s disease (PD) is a neurodegenerative disorder featured by the loss of dopaminergic neurons in the substantia nigra.
The primary motor symptoms of patients with PD are muscular rigidity, akinesia-bradykinesia and resting tremor.
Catalepsy is a well-known symptom of Parkinson's disease. It is characterized by muscle rigidity and fixity of posture for a prolonged period of time (akinesia).
Haloperidol, a neuroleptic drug, induces catalepsy, and is thus used as a model for the screening of new compounds that could potentially reverse catalepsy and in that way improve certain symptoms of Parkinson’s disease.
Anti-parkinsonian drugs are usually tested in this model but other treatments could also be considered. Please feel free to contact us to discuss the feasibility of your study.
☐ Haloperidol-induced catalepsy
☐ Akinesic symptoms of PD
The degree of inhibition / reversion of haloperidol-induced catalepsy is used to measure the potential effect of new drugs on akinesic symptoms of PD.
Graph A :
Time course of Haloperidol-induced catalepsy in the mouse.
Treatment with CSC markedly reduces haloperidol-induced catalepsy.
Graph B :
Reduction of haloperidol-induced catalepsy by CSC during the stable phase (180-270min).